HeartSciences Inc. Files Q2 2025 10-Q
Ticker: HSCSW · Form: 10-Q · Filed: Dec 16, 2024 · CIK: 1468492
| Field | Detail |
|---|---|
| Company | Heartsciences Inc. (HSCSW) |
| Form Type | 10-Q |
| Filed Date | Dec 16, 2024 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 18 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, capital-raising
TL;DR
HeartSciences filed its 10-Q for Oct 31, 2024 - shows warrant activity & paid-in capital.
AI Summary
HeartSciences Inc. filed its 10-Q for the period ending October 31, 2024. The filing details financial activities including common stock warrants and additional paid-in capital from August 1, 2024, to October 31, 2024. It also references a Streeterville Note and consulting services during September 2024, and equity transactions from August 1, 2023, to October 31, 2023.
Why It Matters
This filing provides insight into HeartSciences' financial health and recent capital-raising activities, which can influence investor decisions.
Risk Assessment
Risk Level: medium — The filing indicates ongoing financial activities and capital transactions, which can be complex and carry inherent risks for investors.
Key Numbers
- $0.01 — EPS (Earnings Per Share for the fiscal year ending April 30, 2025)
Key Players & Entities
- HeartSciences Inc. (company) — Filer
- October 31, 2024 (date) — Reporting Period End Date
- August 1, 2024 (date) — Activity Start Date
- October 31, 2023 (date) — Comparative Period End Date
- Streeterville Note (financial_instrument) — Mentioned Financial Obligation
FAQ
What was the total additional paid-in capital for the period ending October 31, 2024?
The filing indicates activity related to 'us-gaap:AdditionalPaidInCapitalMember' for the period of August 1, 2024, to October 31, 2024, but does not provide a specific total dollar amount in this excerpt.
What is the significance of the 'StreetervilleNoteMember' mentioned?
The 'StreetervilleNoteMember' is referenced in the context of financial activities during September 2024, suggesting it is a financial instrument or obligation relevant to the company's operations.
When did HeartSciences Inc. change its former name?
HeartSciences Inc. changed its former name from Heart Test Laboratories, Inc. on July 16, 2009.
What is the company's Standard Industrial Classification code?
The company's SIC code is 3842, categorized under 'ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES'.
What type of preferred stock is mentioned for the period ending April 30, 2024?
The filing mentions 'hscs:SeriesCConvertiblePreferredStockMember' as a type of preferred stock for the period ending April 30, 2024.
Filing Stats: 4,463 words · 18 min read · ~15 pages · Grade level 16.7 · Accepted 2024-12-16 16:03:55
Filing Documents
- hscs-20241031.htm (10-Q) — 1783KB
- hscs-ex31_1.htm (EX-31.1) — 16KB
- hscs-ex31_2.htm (EX-31.2) — 16KB
- hscs-ex32_1.htm (EX-32.1) — 9KB
- hscs-ex32_2.htm (EX-32.2) — 9KB
- 0000950170-24-136607.txt ( ) — 7014KB
- hscs-20241031.xsd (EX-101.SCH) — 1137KB
- hscs-20241031_htm.xml (XML) — 969KB
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 26 Item 4.
Controls and Procedures
Controls and Procedures 26 PART II. OTHER INFORMATION 27 Item 1.
Legal Proceedings
Legal Proceedings 27 Item 1A.
Risk Factors
Risk Factors 27 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 27 Item 3. Defaults Upon Senior Securities 27 Item 4. Mine Safety Disclosures 27 Item 5. Other Information 27 Item 6. Exhibits 28
Signatures
Signatures 32 i HEARTSCIENCES INC.
—FIN ANCIAL INFORMATION
PART I—FIN ANCIAL INFORMATION Ite m 1. Financial Statements. HEARTSCIENCES INC. C ondensed Balance Sheets October 31, April 30, 2024 2024 (Unaudited) ASSETS CURRENT ASSETS: Cash and cash equivalents $ 4,052,120 $ 5,807,648 Inventory, net 652,907 629,179 Prepaid expenses 239,629 183,704 Other current assets 40,374 40,374 Deferred offering costs 704,044 692,988 Total current assets 5,689,074 7,353,893 Property and equipment, net 77,069 97,991 Intangible assets, net 1,592,764 1,589,246 Right-of-use assets, net 418,334 461,983 TOTAL ASSETS $ 7,777,241 $ 9,503,113 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable $ 276,848 $ 448,183 Accrued expenses 369,673 398,331 Current portion of accrued interest expense 5,096 268,813 Operating lease liabilities 110,645 102,293 Current portion of notes payable 2,366,800 500,000 Other current liabilities 173,644 34,147 Total current liabilities 3,302,706 1,751,767 LONG-TERM LIABILITIES Notes payable 49,470 — Accrued expenses 32,103 — Operating lease liabilities, long-term 376,241 434,045 Total long-term liabilities 457,814 434,045 TOTAL LIABILITIES 3,760,520 2,185,812 COMMITMENTS AND CONTINGENCIES (NOTE 2, 4-6, and 8) STOCKHOLDERS' EQUITY Series A, B, and C convertible preferred stock, $ 0.001 par value, 20,000,000 shares authorized and 620,000 designated; 380,440 shares issued and outstanding as of October 31, 2024 and April 30, 2024. 380 380 Common stock, $ 0.001 par value, 500,000,000 shares authorized; 947,821 shares issued and outstanding as of October 31, 2024 and 676,598 shares issued and outstanding as of April 30, 2024. 948 677 Additional paid-in capital 75,512,406 74,678,650 Accumulated deficit ( 71,497,013 ) ( 67,362,406 ) TOTAL STOCKHOLDERS' EQUITY 4,016,721 7,317,301 TOTAL LIABILITIES AND STO